Table 1.
Correlation between methylation of IRF4/IRF5 and the clinicopathological features of the patients
| Characteristics | IRF4 | IRF5 | |||||
|---|---|---|---|---|---|---|---|
| Total | U | M | P‐value | U | M | P‐value | |
| n | 68 | 4 | 64 | 57 | 11 | ||
| Age | |||||||
| Mean | 64.2 | 66.3 | 64.0 | 0.727 | 64.5 | 62.7 | 0.668 |
| SD | 12.1 | 6.7 | 12.4 | 11.7 | 14.9 | ||
| Sex | |||||||
| Male | 45 | 4 | 41 | 0.292 | 19 | 4 | 1.000 |
| Female | 23 | 0 | 23 | 38 | 7 | ||
| Location | |||||||
| Lower | 30 | 2 | 28 | 0.929 | 26 | 4 | 0.458 |
| Middle | 23 | 1 | 22 | 20 | 3 | ||
| Upper | 15 | 1 | 14 | 11 | 4 | ||
| Type | |||||||
| 0 | 4 | 0 | 4 | 0.605 | 3 | 1 | 0.547 |
| 1 | 5 | 0 | 5 | 4 | 1 | ||
| 2 | 26 | 3 | 23 | 20 | 6 | ||
| 3 | 25 | 1 | 24 | 22 | 3 | ||
| 4 | 8 | 0 | 8 | 8 | 0 | ||
| Histology | |||||||
| D | 38 | 0 | 38 | 0.034 | 29 | 9 | 0.096 |
| I | 30 | 4 | 26 | 28 | 2 | ||
| ly | |||||||
| − | 14 | 0 | 16 | 0.566 | 12 | 4 | 0.272 |
| + | 44 | 4 | 48 | 45 | 7 | ||
| v | |||||||
| − | 16 | 0 | 33 | 0.115 | 27 | 6 | 0.749 |
| + | 52 | 4 | 31 | 30 | 5 | ||
| pT | |||||||
| pT1 | 5 | 0 | 5 | 0.225 | 4 | 1 | 0.352 |
| pT2 | 36 | 1 | 35 | 29 | 7 | ||
| pT3 | 25 | 3 | 22 | 22 | 3 | ||
| pT4 | 2 | 0 | 2 | 2 | 0 | ||
| pN | |||||||
| pN0 | 18 | 2 | 16 | 0.145 | 16 | 2 | 0.855 |
| pN1 | 25 | 2 | 23 | 19 | 6 | ||
| pN2 | 14 | 0 | 14 | 12 | 2 | ||
| pN3 | 11 | 0 | 11 | 10 | 1 | ||
| pM | |||||||
| M0 | 57 | 4 | 53 | 1.000 | 47 | 10 | 0.677 |
| M1 | 11 | 0 | 11 | 10 | 1 | ||
| Stage (pTNM, 1997, 5th ed) | |||||||
| 1A | 3 | 0 | 3 | 0.342 | 2 | 1 | 0.511 |
| 1B | 12 | 0 | 12 | 11 | 1 | ||
| 2 | 13 | 3 | 10 | 10 | 3 | ||
| 3A | 12 | 1 | 11 | 9 | 3 | ||
| 3B | 7 | 0 | 7 | 6 | 1 | ||
| 4 | 21 | 0 | 21 | 19 | 2 | ||
| KRAS | |||||||
| − | 64 | 4 | 60 | 1.000 | 55 | 9 | 0.120 |
| + | 4 | 0 | 4 | 2 | 2 | ||
| p53 | |||||||
| − | 53 | 3 | 50 | 1.000 | 42 | 11 | 0.105 |
| + | 15 | 1 | 14 | 15 | 0 | ||
| EBV | |||||||
| − | 60 | 4 | 56 | 1.000 | 55 | 5 | <0.001 |
| + | 8 | 0 | 8 | 2 | 6 | ||
| CIMP | |||||||
| H | 17 | 0 | 14 | 0.035 | 8 | 9 | <0.001 |
| L | 34 | 1 | 33 | 32 | 2 | ||
| N | 17 | 3 | 14 | 17 | 0 | ||
CIMP, CpG island methylator phenotype; EBV, Epstein–Barr virus; IRF4, interferon regulatory factor 4. ly, lymphatic vessels invasion; pN, pathological node stage; pT, pathological tumor stage; pM, pathological metastasis.